Sotera Health (NASDAQ:SHC) Announces Earnings Results

Sotera Health (NASDAQ:SHC) released its quarterly earnings data on Thursday. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02, FiscalAI reports. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The business had revenue of $321.38 million during the quarter, compared to analysts’ expectations of $309.70 million. During the same quarter last year, the business posted $0.20 EPS. The business’s revenue was up 9.2% on a year-over-year basis. Sotera Health updated its FY 2026 guidance to 0.950-1.010 EPS.

Here are the key takeaways from Sotera Health’s conference call:

• Strong second-quarter performance: Revenue rose 8% on a constant-currency basis, adjusted EBITDA increased 8.7%, margins expanded 36 basis points, and adjusted EPS grew 30% to $0.26.
• Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25%-6.75%, adjusted EBITDA growth of 5.75%-7.25%, and adjusted EPS of $0.95-$1.01.
• Sterigenics delivered 7% constant-currency revenue growth, supported by pricing, volume and mix, while Nordion grew 16.7%; Sterigenics also expects second-half growth from favorable shutdown timing, a large customer outsourcing EO sterilization, and the new X-ray facility.
• Net leverage improved to 3.0 times, reaching the company’s long-term target range, while 2026 capital expenditures are expected at $200 million-$225 million for capacity expansions and facility upgrades; management expects a meaningful CapEx reduction in 2027.
• Nelson Labs’ revenue grew 5.4% in constant currency, but segment income margin declined year over year because of higher costs; management continues to forecast a full-year margin in the low-to-mid 30% range.

Sotera Health Stock Down 0.3%

Sotera Health stock traded down $0.05 during mid-day trading on Friday, reaching $18.86. The stock had a trading volume of 3,375,782 shares, compared to its average volume of 3,027,352. Sotera Health has a one year low of $12.94 and a one year high of $19.85. The company has a 50-day moving average price of $17.13 and a two-hundred day moving average price of $16.33. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 33.09 and a beta of 1.77. The company has a debt-to-equity ratio of 3.19, a current ratio of 2.80 and a quick ratio of 2.54.

Wall Street Analyst Weigh In

SHC has been the topic of several research reports. Barclays lifted their price objective on Sotera Health from $19.00 to $22.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings raised Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 9th. Citigroup raised their target price on Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Friday. The Goldman Sachs Group assumed coverage on Sotera Health in a research note on Friday, June 5th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and an average price target of $21.50.

Trending Headlines about Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total transaction of $193,194,516.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 15.36% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sotera Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sculptor Capital LP lifted its position in Sotera Health by 27.2% during the second quarter. Sculptor Capital LP now owns 11,500,000 shares of the company’s stock valued at $127,880,000 after purchasing an additional 2,462,489 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Sotera Health by 4.8% during the 4th quarter. Janus Henderson Group PLC now owns 6,772,059 shares of the company’s stock valued at $119,460,000 after buying an additional 312,191 shares during the period. State Street Corp boosted its stake in shares of Sotera Health by 21.0% in the 4th quarter. State Street Corp now owns 5,965,326 shares of the company’s stock worth $105,228,000 after buying an additional 1,035,457 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Sotera Health by 11.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,160,594 shares of the company’s stock worth $91,036,000 after acquiring an additional 524,012 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of Sotera Health by 1,206.2% in the fourth quarter. AQR Capital Management LLC now owns 2,864,106 shares of the company’s stock worth $50,523,000 after acquiring an additional 2,644,831 shares during the period. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.